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Abstract
Background: Parkinson’s disease is an age-related disease whose pathogenesis is not completely known. Animal
models exist for investigating the disease but not all results can be easily transferred to humans. Therefore,
mathematical or probabilistic models for the human disease are to be constructed in silico in order to predict specific
processes within a cell, such as the dopamine metabolism and transport processes in a neuron.
Results: We present a Systems Biology Markup Language (SBML) model of a whole dopaminergic nerve cell
consisting of 139 reactions and 111 metabolites which includes, among others, the dopamine metabolism and
transport, oxidative stress, aggregation of α-synuclein (αSYN), lysosomal and proteasomal degradation, and
mitophagy. The predictive power of the model was investigated using flux balance analysis for the identification of
steady model states. To this end, we performed six experiments: (i) investigation of the normal cell behavior, (ii)
increase of O2, (iii) increase of ATP, (iv) influence of neurotoxins, (v) increase of αSYN in the cell, and (vi) increase of
dopamine synthesis. The SBML model is available in the BioModels database with identifier MODEL1302200000.
Conclusion: It is possible to simulate the normal behavior of an in vivo nerve cell with the developed model. We
show that the model is sensitive for neurotoxins and oxidative stress. Further, an increased level of αSYN induces
apoptosis and an increased flux of αSYN to the extracellular space was observed.
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Background
Parkinson’s disease (PD) is the second most frequent neu-
rodegenerative disorder after Alzheimer’s disease. The
mean age of onset is in the late 50s [1] and 1% of the
population older than 60 years is affected by PD [2]. The
cell death of the dopaminergic neurons in the substantia
nigra is responsible for typical disease symptoms: tremor,
rigidity, and akinesia. The major genetic factor for PD is
α-synuclein (αSYN). Protein aggregates that are the neu-
ropathological hallmark of PD, called Lewy bodies (LBs),
confirm αSYN as the principal component [3]. Besides
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αSYN,mutations in the genes encoding LRRK2 [4], parkin
[5], PINK1 [6], and DJ-1 [7] are genetically linked to PD.
Until now, the underlying genetic andmolecular mecha-
nisms of PD have not been completely understood. Mittag
et al. showed in their study that it is not possible to
predict the disease risk for PD with top-validated single-
nucleotide polymorphisms, although such a prediction
is possible for type 1 diabetes [8]. Thus, in the case of
PD, genetic markers alone cannot explain the disease
outbreak. Therefore, more complex disease mechanisms
must exist.While many animal models were developed for
biological disease investigations, it is challenging to build
one that elicits all aspects of the PD syndrome during
aging. Some animal models exclusively reflect the symp-
toms of the disease or just a small fraction of them [9].
© 2013 Büchel et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Further, not all findings of the animal models can be eas-
ily transferred to human beings, and it is not possible
to investigate the molecular mechanisms of PD in a liv-
ing human being. Therefore, mathematical models were
developed to obtain insights into the cellular behavior
[10,11]. A common method for the detailed investigation
of these in silico models is flux balance analysis (FBA). It
uses the reaction stoichiometry of the metabolic reactions
to determine the most important cellular fluxes and cell
steady states (where the cellular substance concentrations
are in equilibrium) [12].
In this study, we apply a constraint-based modeling
approach with the aim to derive a mathematical descrip-
tion of the basic dopaminergic nerve cell, whose predic-
tions yield new insights of the disease mechanisms of PD.
The quantitative computational dopaminergic nerve cell
model has been stored in in the Systems Biology Markup
Language (SBML). SBML is a widespread and machine-
readable XML format that can be used for simulating,
storing, and exchanging biological models [13]. It allows
for a detailed description of metabolic reactions and is
able to connect the model’s content to peer-reviewed
databases. Our dopaminergic nerve cell model includes
the complete dopamine (DA) synthesis, metabolism, and
transport introduced by Best et al. [11]. Further, we model
mitochondrial biogenesis and mitophagy [14,15], degra-
dation processes of the lysosome and the proteasome
[16], and reactions of the cell to reactive oxygen species
(ROS) [17] and αSYN [18]. Additionally, the two genes
HtrA2 and PINK1, both of which are involved in the mito-
chondrial stress response [19], are also integrated. The
model is investigated using FBA by assigning different
flux constraints and target functions. The experiments
reproduce the normal behavior of an in vivo dopaminer-
gic nerve cell at steady state and show that an increase
of αSYN amplifies protein aggregation and leads to a
drastically increased flux of αSYN to the extracellular
space. This basic dopaminergic nerve cell model is pub-
licly available at the BioModels database [20] with identi-
fier MODEL1302200000 and can be further extended and
investigated by other researchers to reveal insights of the
underlying mechanism of PD.
Results and discussion
The dopaminergic nerve cell model
The computational model of a dopaminergic nerve cell
was developed and stored in SBML (see Additional
file 1). It includes 111 metabolites and 139 reactions (see
Additional files 2 and 3). The basis of the model com-
prises the publication by Best et al. [11], which math-
ematically describes the synthesis, metabolism, and the
transport of DA in single dopaminergic neuron terminals
(see sub-model 1-3). A detailed comparison of the model
fluxes from Best et al. to our model fluxes is presented
in Additional file 4. In addition, the model was enriched
with information from previously published literature as
well as with data from the databases PANTHER [21],
TRANSPATH [22], STRING [23], Gene Ontology [24],
and the Nature Pathway Interaction Database [25]. A
schematic overview model is shown in Figure 1 and a
detailed image is shown in Additional file 5.
The developed model consists of eleven sub-models,
which are described here in more detail:
Sub-model 1, 2, and 3 - DA synthesis, metabolism,
and transport: DA is synthesized from L-DOPA which is
synthesized fromL-tyrosine with the enzymes aromatic L-
amino acid decarboxylase and tyrosine-hydroxylase (TH).
The degradation of DA to homovanillic acid is cat-
alyzed by monoamine oxidase (MAO) and the catechol-
O-methyl transferase [26]. During this process, toxic side
products can be built, such as salsolinol, which inhibits
MAO and TH [27]. Besides these reactions, the model
includes the release of DA vesicles as well as the re-uptake
via the dopamine transporter (DAT). The interaction of
DA with αSYN, which enhances the protein aggregation
and reaction with ROS, is also included in the SBML
model.
Sub-model 4 - 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine(MPTP): The neurotoxin MPTP is used to
elicit PD symptoms in animal models (mouse or mon-
key). MPTP is the precursor of MPP+, which is imported
into nigrostriatal DA neurons via DAT and irreversibly
inhibits the mitochondrial respiration chain. Next, the
uptake of MPTP causes neuronal cell death. We included
MPTP in our model to represent several drugs that lead to
drug-induced Parkinsonism [28].
Sub-model 5 - Apoptosis: The model includes two
simple mechanisms that induce apoptosis, the first of
which is the release of cytochrome C by defective mito-
chondria, which activates caspase-9. Second, we included
the assumption that protein aggregates enhance the ROS
production and induce apoptosis [3,29]. The process of
apoptosis itself is not modeled in detail because the model
focuses on the procedures that induce apoptosis.
Sub-model 6 - Degradation: The lysosome and the
ubiquitin-proteasome-system (UPS) are responsible for
the degradation of proteins or foreign substances in the
cell. The basic degradation processes of nucleic acids,
polysaccharides, proteins, and lipids by the lysosome are
contained in the model. The UPS is modeled in detail to
investigate the influence of the E3-ligase Parkin on the
ubiquitylation of misfolded proteins [16].
Sub-model 7 - αSYN and LB formation: αSYN, ubiq-
uitin, neurofilaments, and other proteins build the PD
characteristic protein aggregates [18]. The nerve cell
model includes the αSYN aggregation by the interaction
of αSYN with DA and the aggregation enhanced by the
interaction with ROS. Further, the aggregation inhibition
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Figure 1 Schema of the dopaminergic neve cell model. The dopaminergic nerve cell model contains 111 metabolites (red and pink circles) and
139 reactions (rectangles). The different sub-models are labeled and indicated in different colors. Metabolites and reactions that are surrounded by
multiple colors are assigned to multiple sub-models. The most strongly interconnected part of the model is in the middle and consists of αSYN,
ROS, damaged proteins, and mitochondria.
by DJ-1 (see sub-model 8) is modeled as well as the
inhibition of the mitochondrial fusion by DJ-1 [30].
Sub-model 8 - The chaperone DJ-1: DJ-1 is the prod-
uct of the PARK7 gene. Defects in this protein are causal
for an autosomal-recessive form of PD [7] andDJ-1 knock-
out leads to increased ROS production and the elongation
of the mitochondria [31]. DJ-1 has a redox-sensitive chap-
erone function, is an indicator for oxidative stress, and is
able to protect neurons against this form of stress [32].
Themodel includes these protection effects against oxida-
tive stress as well as the function to inhibit the aggregation
and toxic influence of αSYN [14,15].
Sub-model 9 - Mitochondrial quality control: Steady
fusion and fission processes maintain the morphology and
the membrane potential of mitochondria. If a mitochon-
drion is defective it can be repaired through three different
quality control processes: (i) molecular quality control, (ii)
organella quality control, and (iii) cellular quality control
[33]. The first mechanism involves HtrA1/Omi, PINK1,
and TRAP1 and leads to mitochondrial fission and con-
versely OPA1 mediated fusion. In the second mechanism,
the mitochondrion is removed by autophagy involving
PINK1 and Parkin, and VDAC1 or mitofusin [34]. The
thirdmechanism starts if the othermechanisms fail. Then,
the mitochondrion releases pro-apoptotic factors and the
cell dies. The model includes the respiration chain with
ATP production, the three repair mechanisms, and the
production of ROS by defective mitochondria.
Table 1 Parameters and target functions of the flux
balance analyses




Normal nerve cell minApo, maxApo, minDeg, maxDeg -
O2 minApo, maxDeg 0-100
ATP minApo, maxDeg 0-1000
Drug influence (MPTP) minApo, maxDeg 0-100
Increased αSYN flux minApo, maxDeg 0-100
Increased tyrosine flux minApo, maxDeg 0-100
Six experiments were performed. For each experiment, at least two different
FBAs were performed with different target functions and variable flux ranges
that are denoted in the last table column. Abbreviations: minimizing the
output-reaction of the apoptosis (minApo), maximizing the output-reaction of
the apoptosis (maxApo), minimizing the output-reaction of the degradation
(minDeg), maximizing the output-reaction of the degradation (maxDeg),
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
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Sub-model 10 - Protein phosphorylation by PINK1:
The model also represents the phosphorylation of
Parkin, HtrA2/Omi, and TRAP1 by PINK1 [15]. Parkin
inhibits, similar to phosphorylated TRAP1, the release of
cytochrome C and consequently, Parkin and TRAP pre-
vent apoptosis [35-37]. Additionally, Parkin stimulates the
repair of defective mitochondria [38] and TRAP1 inhibits
mitochondrial protein misfolding (see sub-model 9) [39].
Phosphorylation by PINK1 was suggested to activate
the proteolytic activity of HtrA2/Omi and confer some
resistance to mitochondrial stress [40].
Sub-model 11 - molecular units of currency: This
part includes the molecular units of currency, namely O2,
H2O, NAD+, NADH, Fe+3 , Fe+2 , ADP + Pi, and ATP. For
the FBA, these substances are allowed to flow in and out
of the model within the defined ranges.
We restricted our model to autonomous cell events.
The LRRK2 gene, which is the most common autosomal-
dominant gene and an important genetic cause for
sporadic PD, was not included in the core model because
its complete function remains unknown [41]. It is recently
believed that LRKK2 is involved in immune processes
[42].
The nerve cell model was further annotated using
methods from the application KEGGtranslator [43,44]
and published in the BioModels database. It is avail-
able with identifierMODEL1302200000 and as Additional
file 1.
Model analysis
Weperformed six in silico experiments: (i) investigation of
the normal cell behavior, (ii) increase of O2, (iii) increase
of ATP, (iv) influence of neurotoxins, (v) increase of
αSYN in the cell, and (vi) increase of dopamine synthesis
(see Table 1). For each experiment at least two flux balance
analyses were performed with different target functions
and varying input fluxes. The target functions minimal
apoptosis (minApo) and maximal degradation (maxDeg)
were always used for the analysis but maximal apopto-
sis (maxApo) and minimal degradation (minDeg) were
selected only once for the initial model investigation. The
experiments are presented in detail below.
Figure 2 Comparison of the basic-model fluxes. The diagram shows the results of four flux balance analyses of the basic dopaminergic nerve
cell. As target functions, the maximization of apoptosis (maxApo), the minimization of apoptosis (minApo), the maximization of degradation
(maxDeg), and the minimization of degradation (minDeg) were optimized, respectively. Interestingly, the mitochondrial production of ROS by
complex I and the apoptosis initiated by LB can be observed only in the maxApo analysis. Mitophagy is performed in minApo and maxDeg, whereas
the biogenesis is only performed in maxApo and minDeg. Degradation processes appear mainly in the minApo and maxDeg analysis but are
extremely diminished or nonexistent in the maxApo and minDeg analyses.
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Conversion of the healthy cell to a diseased cell
In the first experiment, we investigated the model of a
healthy dopaminergic nerve cell to determine the normal
flux ranges. Compared to the model by Best et al. the
resulting model from our study contains more reactions
with cytosolic dopamine as a substrate. Thus, it was nec-
essary to adapt the suggested initial flux bounds from Best
et al. (see Additional file 4).
In aged cells, there aremore damaged proteins and ROS,
which need to be degraded [17]. A healthy nerve cell is
able to degrade damaged proteins and initiates apoptosis
only if there is no alternative [17,45]. This may also reflect
the cellular behavior of neurons during the disease out-
break of PD. For that reason we selected apoptosis and
degradation fluxes as target functions for the FBA, i.e.,
those functions are gradually maximized during our anal-
yses. The results are depicted in Figure 2 and Table 2. The
initiation and the apoptosis itself are very complexmecha-
nisms [46] and constitute fundamental parts of the model.
We assume that the optimization of the minApo and
maxDeg target analyses best reflects the normal neuronal
cell behavior because cell death is a late event in neurode-
generative diseases, and before initiating apoptosis the
cell degrades damaged cell products [47]. We examined
this assumption by minimizing apoptotic processes in the
FBA and observed increased degradation and increased
ROS elimination processes but no apoptosis. Apoptosis
appears when we maximize the degradation processes
and it even increases during the minDeg analysis. Dur-
ing this analysis, we also observed apoptosis induced by
mitochondria. This flux is also increased in the maxDeg
experiment. In the maxApo analysis, DJ-1 activity and
degradation processes are nearly missing. This is due to
the underlying optimization algorithm of the FBA, which
forces apoptotic processes. Therefore, we used minApo
and maxDeg as target functions for the following experi-
ments.
O2 experiment
In addition to the previous experiment, the input reac-
tion of O2 is included in the optimization function of the
FBA. For both flux balance analyses with target functions
Table 2 Fluxes of the basic model
Fluxes in μM · h−1
Basic model
Reaction (group) maxApo minApo maxDeg minDeg
ROS production (DA) 19.00 19.00 19.56 19.00
ROS production (mitochondria, complex I) 21.15 0.00 0.00 0.00
ROS production (mitochondria, complex III) 46.04 26.05 35.06 23.35
ROS elimination (DJ-1) 0.00 0.00 0.00 0.00
ROS damage (protein) 14.98 22.73 35.17 20.31
ROS damage (mitochondria) 50.00 25.92 28.23 26.21
ROS damage (DNA) 5.00 0.00 0.00 5.00
Apoptosis (LBs) 35.00 0.00 0.00 0.00
Apoptosis (mitochondria) 65.00 0.00 2.40 6.47
Degradation (lysosome) 4.98 10.58 27.27 0.00
Degradation (proteasome) 0.00 0.00 0.00 0.00
Degradation (mitophagy) 0.00 10.43 17.73 0.00
Biogenesis of mitochondria 5.00 0.00 0.00 5.00
Extracellular DA 0.80 0.80 0.80 0.80
αSYN aggregation 36.00 9.89 4.24 10.00
αSYN output reaction 0.00 0.00 0.00 0.00
Toxic effect of αSYN aggregates 0.00 0.00 0.00 0.00
Inhibition of αSYN aggregation by DJ-1 1.00 9.89 4.24 10.00
The table shows the FBA results of the basic dopaminergic nerve cell experiment. Four different target functions were selected for the simulation: (i) minApo, (ii)
maxApo, (iii) minDeg, (iv) maxDeg. The table includes three reactions groups: ‘ROS production (dopamine)’, ‘αSYN aggregation’ and ‘Toxic effects ofαSYN
aggregates’. ‘ROS production (dopamine)’ comprise all reactions of the dopamine synthesis and metabolism, where ROS or ROS-like metabolites are produced. These
reactions are DOPALlikeROS, SalsolinollikeROS, DopaminesyntheseROSout, DOPALSynthesis2, and HVAldehydSynthesis2. ‘αSYN aggregation’ includes the reaction of DA
andαSYN (SNCADopamineAggregation), the reaction of ROS andαSYN (SNCAROSAggregation), and the increasedαSYN expression (SNCAOverexpression). Finally,
‘Toxic effects ofαSYN aggregates’ contains the reactionMitochondriaDamageSNCAAggregates and isdamagedProtein. For each reaction group, the reaction fluxes are
added up to obtain a better overview of the corresponding topic.
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minApo and maxDeg, no flux is observed between 0 μM ·
h−1 and 4 μM · h−1 O2 (see Figure 3). At an input flux
between 4 and 21 μM · h−1 the ROS production dur-
ing the DA synthesis rises, as does the production of
ROS by complex III of the respiratory chain increase.
This rise is higher in the maxDeg experiment than in
the minApo experiment. Futher, an immediate increase
of the αSYN aggregation process can be observed in the
maxDeg experiment, but it falls off at an O2 input flux of
21 μM · h−1. In summary, this experiment shows that at
an O2 input flux of 30 μM · h−1 or higher the cell is in a
stable condition and no apoptosis is initiated.
ATP experiment
In this experiment the energy consumption of the system
is investigated (see Figure 4). The resulting steady state
fluxes show that an ATP flux of at least 266 μM · h−1
up to 512 μM · h−1 is required for the cellular processes.
We observed that the ATP production correlates with
the SNCA input, because this reaction is coupled to the
ATP consumption in the model. Thus, at an ATP input
flux of 370 μM · h−1 the cell produces too much ATP.
Initially, the ATP surplus is transported out of the cell.
But with increasing ATP, more ATP consuming reactions,
such as αSYN input and output reactions, are boosted in
order to gain a solution to the FBA. In conclusion, the
model’s optimal behavior is achieved between an ATP flux
of 266 μM · h−1 and 368 μM · h−1.
MPTP experiment
MPTP is an established neurotoxin to induce PD [48].
In this experiment, we investigated whether the model
behaves like a normal dopaminergic nerve cell. The
results of this experiment are shown in Figure 5. In
both FBA experiments with target function minApo
and maxDeg, the ROS production fluxes of complex
I of the respiratory chain increases steadily. In the
minApo experiment, the degradation flux of the lyso-
some increases in parallel. The same behavior can be
observed for the aggregation of αSYN and the inhibition
Figure 3 Cellular behavior with increasing O2. The four diagrams show the flux changes while the O2 input flux is increased from 0 to
100 μM · h−1. Sub-diagram A and B depict the results of the FBA with target function maxDeg. Sub-diagram C and D display the results of the FBA
with target function minApo. Sub-diagram A and C summarize all fluxes that produce ROS and/or cause damage in the cell. In contrast,
sub-diagram B and D contain all fluxes that are considered to be responses or consequences of fluxes shown in sub-diagram A to retain the normal
cellular function.
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Figure 4 Cellular behavior with increasing ATP production. The four diagrams show the flux changes while the ATPase input flux is increased
from 0 to 1000 μM · h−1. Sub-diagram A and B depict the results of the FBA with target function maxDeg. Sub-diagram C and D display the results
of the FBA with target function minApo. Sub-diagram A and C summarize all fluxes that produce ROS and/or cause damage in the cell. In contrast,
sub-diagram B and D contain all fluxes that are considered responses or consequences of fluxes shown in sub-diagram A to retain the normal
cellular function.
of the aggregation process by DJ-1. During the FBA
with target function minApo, no apoptosis is observed
which is due to the FBA simulation behavior. However,
with the maxDeg FBA, apoptosis starts at an MPTP
input flux of 23 μM · h−1, which is initiated by the
mitochondria.
α-synuclein experiment
Here, we investigated the influence of the αSYN con-
centration in the dopaminergic nerve cell (Figure 6)
by performing two FBA simulations with minApo and
maxDeg, respectively, as target functions. Point muta-
tions in SNCA lead to a higher propensity to aggregate
as Lewy bodies [49,50]. To simulate this behavior, the
αSYN flux was steadily increased from 0 to 100 μM · h−1
(see Figure 6). The increased aggregation tendency could
be confirmed by our model, where the αSYN aggrega-
tion continuously rises from 1 μM · h−1 to 31 μM · h−1.
In parallel, the toxic effects of αSYN aggregates increase
(see Figure 6A). In contrast, the ROS production of DA
metabolism decreases as well as the damage of ROS for
proteins in both experiments. In the minApo experiment,
a steady inhibition of αSYN aggregation by DJ-1 with a
flux of 8 μM·h−1 exists, but it decreases at anαSYN input
flux of 13 μM · h−1.
In conclusion, there is no essential contribution of
DJ-1 towards inhibiting αSYN aggregation in the two
FBA experiments. For an αSYN input flux higher than
78 μM · h−1, the FBA, with respect to the target func-
tion minApo, shows unexpected fluctuations in the ROS
production flux of the DA synthesis and in the αSYN
aggregation flux (see Figure 6C). This observation can be
explained by the defined flux ranges of the DA synthe-
sis reactions. Compared to all other model constraints,
these bounds are defined in a very narrow range due to the
knowledge that some reactions proceed slower than oth-
ers. Therefore, reactions with larger flux ranges need to be
divided, and this separation causes the observed behavior.
Another interesting effect is that the αSYN output flux
that transports αSYN to the extracellular space increases
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Figure 5 Cellular behavior after cell penetration with MPTP. The four diagrams show the flux changes while the MPTP input flux is increased
from 0 to 100 μM · h−1. Sub-diagram A and B depict the results of the FBA with target function maxDeg. Sub-diagram C and D display the results
of the FBA with target function minApo. Sub-diagram A and C summarize all fluxes that produce ROS and/or cause damage in the cell. In contrast,
sub-diagram B and D contain all fluxes that are considered responses or consequences of fluxes shown in sub-diagram A to retain the normal
cellular function.
simultaneously with the rise of the αSYN input flux with a
small peak at a flux of 87 μM·h−1. This behavior stabilizes
at an αSYN input flux of 65 μM · h−1 for maxDeg and
at a flux of 75 μM · h−1 for minApo FBA. Apoptosis is
only observed in the maxDeg FBA and is initiated by the
aggregation of αSYN.
DA experiment
Galvin suggests that 3,4-dihydroxyphenylacetaldehyde, a
metabolite of the DA metabolism, may influence the
development of oxidative stress and the interaction with
αSYN [51]. In the last experiment, we increased the tyro-
sine input flux from 0 to 100 μM · h−1 because this
is the precursor flux to induce the DA metabolism (see
Figure 7). In this experiment, we could not observe any
apoptotic processes during the FBA with target func-
tion maxDeg or minApo. There is a slight occurrence of
αSYN aggregation in both flux balance analyses, but an
increased lysosomal degradation at the same time. We
observed a constant ROS production due to the increased
DA production and an increased ROS production by
complex I in the respiratory chain, which affects damaged
proteins in this experiment. We could not observe any
damage of mitochondria or DNA.
In summary, we observed that a higher DA cell concen-
tration is not causal for PD but it can positively stimulate
its development by producing ROS.
Conclusion
In this study, a basic dopaminergic nerve cell model
was generated and made available in the BioModels
database. This model contains DA synthesis, metabolism
and release, the respiration chain and anti-oxidative
defense mechanisms, the degradation system represented
by mitophagy, the lysosome and the proteasome, as well
as the apoptosis pathway. Besides these basic cell func-
tions, the influence of ROS, DJ-1, Parkin, and neurotoxins
weremodeled. The behavior of themodel was investigated
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Figure 6 Effect of increased αSYN flux in the dopaminergic nerve cell. The four diagrams show the flux changes while the αSYN input flux is
increased from 0 to 100 μM · h−1. Sub-diagram A and B depict the results of the FBA with target function maxDeg. Sub-diagram C and D display
the results of the FBA with target function minApo. Sub-diagram A and C summarize all fluxes that produce ROS and/or cause damage in the cell. In
contrast, sub-diagram B and D contain all fluxes that are considered responses or consequences of fluxes shown in sub-diagram A to retain the
normal cellular function.
using FBA. We showed that an increased DA concentra-
tion in the cell produces more ROS but does not induce
cell death. An increased αSYN input flux induces ROS
production, mitophagy, and finally apoptosis. Addition-
ally, we observed thatαSYNwas permanently transported
out of the cell. The cellular death induced by the neuro-
toxin MPTP was also investigated. The results confirmed
that the cell model shows the same behavior as a normal
nerve cell.
The developed SBML model is a core model of a
dopaminergic cell, which contains the essential cellular
processes. It can be easily extended with further exper-
imental knowledge and assumptions. Thus, the model
presented in this work can be used as a basis to con-
duct further in silico studies and to investigate PD in more
detail.
Methods
We developed six different experiments for the identifi-
cation of steady model states and applied several FBAs
with different target functions. Each experiment simu-
lated different cell states and was performed using the
simulation tool VANTED (version 2.01, [52]) and the
add-on FBA-Sim Vis [53]. VANTED is an application for
visualizing and investigating graphs and biological net-
works. Further, VANTED offers the possibility to inves-
tigate these networks statistically [52]. The VANTED
add-on FBA-Sim Vis enables the performance of FBAs
and the dynamic visualization of the resulting fluxes.
The fluxes are calculated using the COBRA toolbox
[54] and an adapted version of the Clp simplex solver
[53].
Flux balance analyses
We performed six different experiments with the appli-
cation VANTED including the add-on FBA-Sim Vis:
(i) investigation of the normal cell behavior, (ii) increase
of O2, (iii) increase of ATP, (iv) influence of neurotox-
ins, (v) increase of αSYN in the cell, and (vi) increase of
dopamine synthesis (see Table 1).
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Figure 7 Investigation of an increased DA amount in the nerve cell. The four diagrams show the flux changes while the tyrosine input flux is
increased from 0 to 100 μM · h−1. Sub-diagram A and B depict the results of the FBA with target function maxDeg. Sub-diagram C and D display
the results of the FBA with target function minApo. The tyrosine input reaction acts as precursor flux for the DA synthesis and metabolism in the
nerve cell model. If this flux is increased, the DA content in the cell rises. Sub-diagram A and C summarize all fluxes that produce ROS and/or cause
damage in the cell. In contrast, sub-diagram B and D contain all fluxes that are considered responses or consequences of fluxes shown in
sub-diagram A to retain the normal cellular function.
Bounds for each flux must be defined prior to
performing an FBA. We took the flux values from
Best et al. with a range of ± 10 % of the original values
for the DA synthesis, metabolism, and transport [11] (see
Additional files 3 and 4). Since the complete dopamin-
ergic nerve cell model contains more reactions than the
model by Best et al., the lower bound values of the reac-
tion OMSynthesis1, OMSynthesis2, HVASynthesis3, and
HVASynthesis4 need to be set to 0 in order to enable the
performance of a complete FBA.
If it is well-known from experiments and literature
that some reactions appear rarely or proceed slowly, the
upper bound can be restricted to a maximum of 30 μM ·
h−1. For all other reactions, a flux range between 0 and
100 μM · h−1 was defined.
Besides the flux bounds, it is necessary to define
those reactions that should be minimized or maximized.
These fluxes are also called target functions. In our
experiments, we always minimized or maximized the
apoptosis or degradation fluxes. The experiments and the
corresponding fluxes are listed in Table 1.
Additional files
Additional file 1: SBMLmodel of the dopaminergic nerve cell. The
SBML file contains the annotated SBML model of the dopaminergic nerve
cell.
Additional file 2: Reactions of the dopaminergic nerve cell model.
This table describes all reactions of the dopaminergic nerve cell model in
detail with name and flux ranges.
Additional file 3: Entities of the dopaminergic nerve cell model. This
spreadsheet lists all model entities that are used in the dopaminergic nerve
cell model. It also includes a description for each entity, as well as
identifiers to commonly used databases.
Additional file 4: Comparison of the mathematical model by Best
et al. to the dopamine sub-model of the dopaminergic nerve cell. This
file presents the comparison of the mathematical model by Best et al. to
the sub-model of the dopaminergic nerve cell containing dopamine
synthesis, metabolism, and transport. It lists in detail the adjusted flux
ranges of the initial model and the result of the FBA of this sub-model.
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Additional file 5: Detailed model of the dopaminergic nerve cell. This
file contains the visualization of the dopaminergic nerve cell model with its
139 reactions and 111 metabolites in detail. The metabolites are depicted
as circles and the reactions as rectangles. Red circles visualize all reagents
and products, whereas pink circles visualize units of currency. Reactions are
colored blue. Reactions with the suffix ‘IN’ represent input reactions
transporting metabolites in the cell (light green) and reactions with the
suffix ‘OUT’ represent the corresponding output reactions (dark green).
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